JNJ-26854165 (Serdemetan)

Catalog No.S1172

JNJ-26854165 (Serdemetan) Chemical Structure

Molecular Weight(MW): 328.41

JNJ-26854165 (Serdemetan) acts as a HDM2 ubiquitin ligase antagonist and also induces early apoptosis in p53 wild-type cells, inhibits cellular proliferation followed by delayed apoptosis in the absence of functional p53. Phase 1.

Size Price Stock Quantity  
In DMSO USD 140 In stock
USD 110 In stock
USD 370 In stock
USD 970 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 6 Publications

6 Customer Reviews

  • Mol Pharmacol 2014 85(3), 408-19. JNJ-26854165 (Serdemetan) purchased from Selleck.

    Sci Rep 2014 4, 4663. JNJ-26854165 (Serdemetan) purchased from Selleck.

  • Sci Rep 2014 4, 4663. JNJ-26854165 (Serdemetan) purchased from Selleck.

    Sci Rep 2014 4, 4663. JNJ-26854165 (Serdemetan) purchased from Selleck.

  • J Nat Med 2013 10.1007/s11418-014-0825-0. JNJ-26854165 (Serdemetan) purchased from Selleck.

    Curr Protoc Chem Biol 2013 5(3), 195-212. JNJ-26854165 (Serdemetan) purchased from Selleck.

Purity & Quality Control

Choose Selective p53 Inhibitors

Biological Activity

Description JNJ-26854165 (Serdemetan) acts as a HDM2 ubiquitin ligase antagonist and also induces early apoptosis in p53 wild-type cells, inhibits cellular proliferation followed by delayed apoptosis in the absence of functional p53. Phase 1.
Targets
p53 [1]
(Cell-free assay)		 HDM2 [1]
(Cell-free assay)		 Mdm2 [2]
(Cell-free assay)
In vitro

JNJ 26854165 is a novel tryptamine derivative which activates p53 and acts as a HDM2 ubiquitin ligase antagonist. JNJ 26854165 inhibits cell growth and induces apoptosis in leukemia cell lines with IC50 values of 0.24, 0.33, 0.32 and 0.44 μM at 72 hours for OCI-AML-3, MOLM-13, NALM-6 and REH cells, respectively. In addition, JNJ 26854165 accelerates proteasome-mediated degradation of p21 and antagonizes the transcriptional induction of p21 by p53. It also induces S-phase delay and upregulates E2F1 expression in p53 mutant cells, resulting in preferential apoptosis of S-phase cells. [1] JNJ 26854165 is an oral Mdm2 inhibitor which can inhibit the interaction of Mdm2-p53 complex with the proteasome and increase p53 levels by binding to RING domain of Mdm2. [2] A recent study shows that JNJ 26854165 inhibits clonogenic survival in four human cancer cell lines: H460, A549, p53-WT-HCT116, and p53-null-HCT116. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
KU-19-19 cell NEPGUohIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mmi0TY5pcWKrdHnvckBw\iCqdX3hckBMXS1zOT2xPUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvQTN{M{[g{txO M4nheHNCVkeHUh?=
H4 cell Mn;6S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYHJcohq[mm2aX;uJI9nKGi3bXHuJGg1KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS5yNkewO{DPxE1? M2rLN3NCVkeHUh?=
KGN cell NF\MTXVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mm[0TY5pcWKrdHnvckBw\iCqdX3hckBMT05iY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLk[yNFUh|ryP NYWxcWU3W0GQR1XS
786-0 cell MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NV7BT5Z4UW6qaXLpeIlwdiCxZjDoeY1idiB5OE[tNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPzJ7OEmg{txO NXXGdoNiW0GQR1XS
769-P cell NGPPRZFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXrJcohq[mm2aX;uJI9nKGi3bXHuJFc3QS2SIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT64NlIzPCEQvF2= M3T2cXNCVkeHUh?=
K5 cell M1HTXmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVLJcohq[mm2aX;uJI9nKGi3bXHuJGs2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi5yMU[yOEDPxE1? MVnTRW5ITVJ?
MLMA cell MnGyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGmzWW9KdmirYnn0bY9vKG:oIHj1cYFvKEuRU1OtNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvODN{MUeg{txO MlfEV2FPT0WU
MLMA cell NHu0NFRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmDTTY5pcWKrdHnvckBw\iCqdX3hckBOVE2DIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj6yPFcxOyEQvF2= MXTTRW5ITVJ?
EW-7 cell NEH2bphIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1HWRmlvcGmkaYTpc44hd2ZiaIXtZY4hTVdvNzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuN|I3QTVizszN M{XONXNCVkeHUh?=
SW1088 cell Ml7GS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1G0fWlvcGmkaYTpc44hd2ZiaIXtZY4hW1dzMEi4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk45ODZ3MTFOwG0> NYnsV2g2W0GQR1XS
MC-IXC cell MX;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1m5NGlvcGmkaYTpc44hd2ZiaIXtZY4hVUNvSWjDJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk45Pzd7MjFOwG0> MYnTRW5ITVJ?
NCI-H2052 cell M1fZe2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUjJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkC1NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvODhzNUeg{txO NHnsdo9USU6JRWK=
IGR-1 cell MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEPRboZKdmirYnn0bY9vKG:oIHj1cYFvKEmJUj2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4yOjB{ODFOwG0> MYDTRW5ITVJ?
DSH1 cell NGDtXJNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MUfJcohq[mm2aX;uJI9nKGi3bXHuJGRUUDFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|LkK0Nlk3KM7:TR?= MlHQV2FPT0WU
PA-1 cell MmLaS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGjYXFFKdmirYnn0bY9vKG:oIHj1cYFvKFCDLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlMxODV7zszN MkmxV2FPT0WU
SK-MEL-3 cell MlzwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYLGOYhPUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3NSWwuOyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTNwM{GyNFch|ryP NYnVU29bW0GQR1XS
SW900 cell NVrBcZc2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Ml\pTY5pcWKrdHnvckBw\iCqdX3hckBUXzlyMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuOFgzPTVizszN MojhV2FPT0WU
CAKI-1 cell MkLIS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MluxTY5pcWKrdHnvckBw\iCqdX3hckBESUuLLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlUzPzN6IN88US=> MYfTRW5ITVJ?
ES1 cell M{XD[2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NG\ZV4xKdmirYnn0bY9vKG:oIHj1cYFvKEWVMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuOVI5QTdizszN Ml\YV2FPT0WU
SK-N-DZ cell MlrDS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NF\jW|VKdmirYnn0bY9vKG:oIHj1cYFvKFONLV6tSHoh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjZ{NUm1JO69VQ>? M4jyNnNCVkeHUh?=
RH-1 cell Mkn5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUHJcohq[mm2aX;uJI9nKGi3bXHuJHJJNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|Lk[4OFY{KM7:TR?= M4jXNnNCVkeHUh?=
ES8 cell M{Hv[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVrJcohq[mm2aX;uJI9nKGi3bXHuJGVUQCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTNwNkm3NFIh|ryP MojKV2FPT0WU
NEC8 cell NHjxRWxIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnPpTY5pcWKrdHnvckBw\iCqdX3hckBPTUN6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz63Olk5OiEQvF2= NUfQ[29lW0GQR1XS
LNCaP-Clone-FGC cell NVXJcmc1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NI\XcoJKdmirYnn0bY9vKG:oIHj1cYFvKEyQQ3HQMWNtd26nLV\HR{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvQDN3M{[g{txO MnjmV2FPT0WU
HCE-4 cell NFTHNGFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4Dr[GlvcGmkaYTpc44hd2ZiaIXtZY4hUEOHLUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlk5ODdizszN NVXtVId{W0GQR1XS
U-118-MG cell MXfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFPaN4lKdmirYnn0bY9vKG:oIHj1cYFvKFVvMUG4MW1IKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC5yMUC2OkDPxE1? MUTTRW5ITVJ?
GI-ME-N cell MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHXPWIdKdmirYnn0bY9vKG:oIHj1cYFvKEeLLV3FMW4h[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjB6N{m2JO69VQ>? NETrTFhUSU6JRWK=
LB1047-RCC cell NVuzTGo5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mo[yTY5pcWKrdHnvckBw\iCqdX3hckBNSjFyNEetVmNEKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC5zNkG0N{DPxE1? NUPXTZM3W0GQR1XS
HT-1080 cell M1j1[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MX;Jcohq[mm2aX;uJI9nKGi3bXHuJGhVNTFyOECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlE6QTJzIN88US=> MlfPV2FPT0WU
NB69 cell MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3TKUWlvcGmkaYTpc44hd2ZiaIXtZY4hVkJ4OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuN|UxPDdizszN Mm\FV2FPT0WU
NCI-H1693 cell NYOxbYp1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MmC0TY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG2PVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjR2OEm1JO69VQ>? MlnlV2FPT0WU
HSC-3 cell NIXGNFRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmiwTY5pcWKrdHnvckBw\iCqdX3hckBJW0NvMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuOFk6OzNizszN MoD1V2FPT0WU
MDA-MB-231 cell NXvGc|Q2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUjSSIs5UW6qaXLpeIlwdiCxZjDoeY1idiCPRFGtUWIuOjNzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND61OVg6QSEQvF2= M{PqbHNCVkeHUh?=
HOS cell NYeybGVjT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVLxcGgzUW6qaXLpeIlwdiCxZjDoeY1idiCKT2OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Mlc5PjNizszN MXPTRW5ITVJ?
BT-549 cell NXO3O3dvT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnzrTY5pcWKrdHnvckBw\iCqdX3hckBDXC13NEmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Mlc5QDdizszN MXrTRW5ITVJ?
NB17 cell MojZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXGySG5EUW6qaXLpeIlwdiCxZjDoeY1idiCQQkG3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE44QDl5NjFOwG0> MXnTRW5ITVJ?
5637 cell MYPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NV;HN2tuUW6qaXLpeIlwdiCxZjDoeY1idiB3NkO3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE44QTZ3MjFOwG0> NWi5TnpDW0GQR1XS
OVCAR-8 cell MUDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlTLTY5pcWKrdHnvckBw\iCqdX3hckBQXkODUj24JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE46OjR|NjFOwG0> NVHtVnFrW0GQR1XS
G-402 cell Ml;jS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXe0W5Q3UW6qaXLpeIlwdiCxZjDoeY1idiCJLUSwNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvQTNyM{Wg{txO NXrleldsW0GQR1XS
BB30-HNC cell Ml\oS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkTRTY5pcWKrdHnvckBw\iCqdX3hckBDSjNyLVjOR{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvODd{MUig{txO NITwNXpUSU6JRWK=
HCC1806 cell NH:ybJdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXzJcohq[mm2aX;uJI9nKGi3bXHuJGhESzF6ME[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlA5OzN7IN88US=> NHf5TJNUSU6JRWK=
COLO-800 cell NWDlS4ZvT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M{LaOmlvcGmkaYTpc44hd2ZiaIXtZY4hS0:OTz24NFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjF{NkSg{txO M4nEfXNCVkeHUh?=
FADU cell M4\DdGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NIqwUItKdmirYnn0bY9vKG:oIHj1cYFvKE[DRGWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlM3PTV5IN88US=> NV;TPFJGW0GQR1XS
NCI-H1651 cell M1HyVmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Ml7hTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG2OVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjN7NEC5JO69VQ>? NYruUJZKW0GQR1XS
AGS cell NI\vNWVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Ml7VTY5pcWKrdHnvckBw\iCqdX3hckBCT1NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13LkS3O|EyKM7:TR?= MXTTRW5ITVJ?
CHP-212 cell MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEPIUWtKdmirYnn0bY9vKG:oIHj1cYFvKEOKUD2yNVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjN7NEC5JO69VQ>? MlHxV2FPT0WU
YAPC cell MmjMS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MnTpTY5pcWKrdHnvckBw\iCqdX3hckB[SVCFIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT60O|cyOSEQvF2= MUnTRW5ITVJ?
GOTO cell NVXmVINXT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NEDsRmVKdmirYnn0bY9vKG:oIHj1cYFvKEeRVF:gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlQ6PTd4IN88US=> NFTXVFRUSU6JRWK=
KYSE-510 cell NYjZPWJ3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHTrclVKdmirYnn0bY9vKG:oIHj1cYFvKEu\U1WtOVExKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS53MUGg{txO M2rpWXNCVkeHUh?=
NCI-H2342 cell M3zyZ2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1HkUmlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyN|QzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS53M{K3PEDPxE1? NIHlXXdUSU6JRWK=
BFTC-905 cell NYjR[FR7T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MofITY5pcWKrdHnvckBw\iCqdX3hckBDTlSFLUmwOUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPjJ6M{Wg{txO MUHTRW5ITVJ?
EW-16 cell Mny3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVLJcohq[mm2aX;uJI9nKGi3bXHuJGVYNTF4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT63NlA6OyEQvF2= MXjTRW5ITVJ?
SK-MEL-30 cell MV3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVvJcohq[mm2aX;uJI9nKGi3bXHuJHNMNU2HTD2zNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPzR3NEOg{txO MnjPV2FPT0WU
HLE cell NV[3dYt4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFPuSZdKdmirYnn0bY9vKG:oIHj1cYFvKEiORTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuO|c1QDlizszN NWPxeI9lW0GQR1XS
T98G cell MkDOS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWr5eXdUUW6qaXLpeIlwdiCxZjDoeY1idiCWOUjHJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU44QTZ|NTFOwG0> NXHBcJNxW0GQR1XS
HUTU-80 cell NELFclNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXzuWJJJUW6qaXLpeIlwdiCxZjDoeY1idiCKVWTVMVgxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS56NEKyPEDPxE1? NYPsfmdvW0GQR1XS
NOS-1 cell NYq4SHNxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MmnNTY5pcWKrdHnvckBw\iCqdX3hckBPV1NvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuPVQ4PjZizszN NEPpU5RUSU6JRWK=
SW780 cell MUPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1iwb2lvcGmkaYTpc44hd2ZiaIXtZY4hW1d5OECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21Mlk3QTR7IN88US=> NW\p[lhPW0GQR1XS
KYSE-180 cell MnjjS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MV3Jcohq[mm2aX;uJI9nKGi3bXHuJGt[W0VvMUiwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU46PzZ3NDFOwG0> MVLTRW5ITVJ?
MDA-MB-361 cell M2TlOmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MX;Jcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2zOlEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02Njl6NkS3JO69VQ>? MmTyV2FPT0WU
SNU-C2B cell NHzUN|RIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmfDTY5pcWKrdHnvckBw\iCqdX3hckBUVlVvQ{LCJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok4xOTF|ODFOwG0> M2HZOXNCVkeHUh?=
NCI-H661 cell NFnYcJRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{Ozd2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi2OlEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03NjB4OUSg{txO NYTmeZBRW0GQR1XS
OE33 cell NF3JO2pIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVPP[4xZUW6qaXLpeIlwdiCxZjDoeY1idiCRRUOzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok4yPDN6OTFOwG0> M1ToNHNCVkeHUh?=
TYK-nu cell M3rte2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlXFTY5pcWKrdHnvckBw\iCqdX3hckBVYUtvboWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlIyQDZ|IN88US=> NX62enI{W0GQR1XS
COLO-792 cell MmK5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVjJcohq[mm2aX;uJI9nKGi3bXHuJGNQVE9vN{myJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok4zPTJzOTFOwG0> NH25XmRUSU6JRWK=
HEL cell MojkS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MoLsTY5pcWKrdHnvckBw\iCqdX3hckBJTUxiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD14LkK2O|Yh|ryP MlHLV2FPT0WU
D-566MG cell M4DiV2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3jmdWlvcGmkaYTpc44hd2ZiaIXtZY4hTC13Nk\NS{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvOzN2OUGg{txO NIjxNoRUSU6JRWK=
U031 cell MUfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEfETYRKdmirYnn0bY9vKG:oIHj1cYFvKFVyM{GgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlQyQDF4IN88US=> Mo\QV2FPT0WU
COR-L23 cell NFrWT5VIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkTtTY5pcWKrdHnvckBw\iCqdX3hckBEV1JvTEKzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok41OzN2NjFOwG0> MmLCV2FPT0WU
NCI-H2452 cell M2TnOmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NH3WNItKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlQ2OiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTZwNUKyPFEh|ryP NX:4XYNOW0GQR1XS
BB65-RCC cell M1HoR2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2nGNmlvcGmkaYTpc44hd2ZiaIXtZY4hSkJ4NT3SR2Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03NjZ2NUmg{txO NH23XpVUSU6JRWK=
CAL-33 cell Mo\yS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NE\PNlNKdmirYnn0bY9vKG:oIHj1cYFvKEODTD2zN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvPjV4NkWg{txO MlrUV2FPT0WU

... Click to View More Cell Line Experimental Data
In vivo JNJ 26854165 leads to significant differences in EFS distribution in 17 of the 36 (47%) evaluable solid tumor xenografts and in 5 of 7 (71%) of the evaluable ALL xenografts using a dose of 20 mg/kg administered via oral gavage daily for 5 days, repeated for 6 weeks. [4]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: OCI-AML-3, MOLM-13, NB4 and U937 cells
  • Concentrations: 0-10 μM
  • Incubation Time: 72 hours
  • Method: Cell lines are maintained in RPMI 1640 medium containing 10% heat-inactivated fetal calf serum (FCS). OCI-AML-3, MOLM-13, NB4 and U937 cells are derived from acute myelogenous leukemia (AML) patients, K562 from a chronic myelogenous leukemia (CML) patient in blast crisis, and NALM-6, REH, P12-ICHIK
    (Only for Reference)
Animal Research:[4]
+ Expand
  • Animal Models: CB17SC scid-/- female mice.
  • Formulation: JNJ-26854165 is dissolved in DMSO and then diluted in water.
  • Dosages: ≤20 mg/kg
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 66 mg/mL (200.96 mM)
Ethanol 2 mg/mL (6.08 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
1% DMSO+30% polyethylene glycol+1% Tween 80
For best results, use promptly after mixing. 		30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 328.41
Formula

C21H20N4
CAS No. 881202-45-5
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field
selleck catalog

p53 Signaling Pathway Map

Related p53 Products

  • MI-773 (SAR405838) New

    MI-773 (SAR405838) is an orally available MDM2 antagonist with Ki of 0.88 nM. Phase 1.

  • A-1210477 New

    A-1210477 is a potent and selective MCL-1 inhibitor with Ki and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.

  • RITA (NSC 652287)

    RITA (NSC 652287) induces both DNA-protein and DNA-DNA cross-links with no detectable DNA single-strand breaks, and also inhibits MDM2-p53 interaction by targeting p53.

    Features:Inducer of DNA cross-links, not a DNA intercalator.

  • Pifithrin-α (PFTα) HBr

    Pifithrin-α is an inhibitor of p53, inhibiting p53-dependent transactivation of p53-responsive genes.

  • Tenovin-1

    Tenovin-1 protects against MDM2-mediated p53 degradation, which involves ubiquitination, and acts through inhibition of protein-deacetylating activities of SirT1 and SirT2.

  • Tenovin-6

    Tenovin-6 is a small molecule activator of p53 transcriptional activity.

  • NSC 319726

    NSC319726 is a p53(R175) mutant reactivator, exhibits growth inhibition in cells expressing mutant p53, with IC50 of 8 nM for p53(R175) mutant, shows no inhibition for p53 wild-type cells.

    Features:An allele-specific p53 mutant reactivator.

  • Pifithrin-μ

    Pifithrin-μ is a specific p53 inhibitor by reducing its affinity to Bcl-xL and Bcl-2, and also inhibits HSP70 function and autophagy.

  • Z-VAD-FMK

    Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.

    Features:A key compound for apoptosis studies.

Tags: buy JNJ-26854165 (Serdemetan) | JNJ-26854165 (Serdemetan) supplier | purchase JNJ-26854165 (Serdemetan) | JNJ-26854165 (Serdemetan) cost | JNJ-26854165 (Serdemetan) manufacturer | order JNJ-26854165 (Serdemetan) | JNJ-26854165 (Serdemetan) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID